|
1) 竹内 勤. 抗TNF製剤による治療. 現代医療. 2004; 36: 1540-6
|
|
|
|
2) Holgate ST. Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease. Cytokine. 2004; 28(4-5): 152-7
|
|
|
|
|
|
3) Holgate ST, Holloway J, Wilson S, et al. Understanding the pathophysiology of severe asthma to generate new therapeutic oppor-tunities. J Allergy Clin Immunol. 2006; 117: 496-506
|
|
|
|
|
4) Broide DH, Lotz M, Cuomo AJ, et al. Cytokines in symptomatic asthma airways. J Allergy Clin Immunol. 1992; 89: 958-67
|
|
|
|
|
|
5) Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFα) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax. 2005; 60: 1012-8
|
|
|
|
|
|
6) Silvestri M, Bontempelli M, Giacomelli M, et al. High serum levels of tumour necrosis factor-α and interleukin-8 in severe asthma: markers of systemic inflammation？ Clin Exp Allergy. 2006; 36: 1373-81
|
|
|
|
|
|
7) Thomas PS, Yates DH, Barnes PJ. Tumor necrosis factor-α increases airway responsiveness and sputum neutrophilia in normal human subjects. Am J Respir Crit Care Med. 1995; 152: 76-80
|
|
|
|
|
|
8) Thomas PS, Heywood G. Effects of inhaled tumour necrosis factorα in subjects with mild asthma. Thorax. 2002; 57: 774-8
|
|
|
|
|
|
9) Kikuchi S, Kikuchi I, Hagiwara K, et al. Association of tumor necrosis factor-α and neutrophilic inflammation in severe asthma. Allergol Int. 2005; 54: 621-5
|
|
|
|
|
10) Kikuchi I, Kikuchi S, Kobayashi T, et al. Eosinophil trans-basement membrane migration induced by interleukin-8 and neutrophils. Am J Respir Cell Mol Biol. 2006; 34: 760-5
|
|
|
|
|
|
11) Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factorα in refractory asthma. N Engl J Med. 2006; 354: 697-708
|
|
|
|
|
|
12) Erin EM, Leaker BR, Nicholson GC, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-α in asthma. Am J Respir Crit Care Med. 2006; 174: 753-62
|
|
|
|
|
|
13) 田中明彦, 美濃口健治. 抗TNF-α療法から見る気管支喘息へのアプローチ. 分子呼吸器病. 2006; 10: 424-8
|
|
|
|
|
|
14) Barnes PJ. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol. 2007; 119: 1055-62
|
|
|
|
|
|
15) Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996; 153: 530-4
|
|
|
|
|
|
16) Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 163: 349-55
|
|
|
|
|
|
17) Churg A, Wang RD, Tai H, et al. Tumor necrosis factor-α drives 70% of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med. 2004; 170: 492-8
|
|
|
|
|
|
18) Langen RC, Schols AM, Kelders MC, et al. Muscle wasting and impaired muscle regenera-tion in a murine model of chronic pulmonary inflammation. Am J Respir Cell Mol Biol. 2006; 35: 689-96
|
|
|
|
|
|
19) van der Vaart H, Koeter GH, Postma DS, et al. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005; 172: 465-9
|
|
|
|
|
|
20) Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 175: 926-34
|
|
|
|
|
|
21) Barnes PJ. Unexpected failure of anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 175: 866-7
|
|
|
|
|
|
22) Sevenoaks MJ, Stockley RA. Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity-a common inflammatory phenotype？ Respir Res. 2006; 7: 70
|
|
|
|
|
|
23) Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malig-nancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006; 295: 2275-85
|
|
|
|
|
|
24) 星野友昭. 間質性肺炎の新規治療薬. 呼吸と循環. 2006; 54: 1077-82
|
|
|
|
|
25) Denys BG, Bogaerts Y, Coenegrachts KL, et al. Steroid-resistant sarcoidosis: is antagonism of TNF-α the answer？ Clin Sci (Lond). 2007; 112: 281-9
|
|
|
|
|
|
26) Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006; 174: 795-802
|
|
|
|
|
|
27) Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005; 352: 351-61
|
|
|
|
|
|
28) Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-α blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford). 2002; 41: 1303-7
|
|
|
|
|
|
29) Mukhtyar C, Luqmani R. Current state of tumour necrosis factorα blockade in Wegener's granulomatosis. Ann Rheum Dis. 2005; 64(Suppl 4): iv31-6. Review
|
|
|
|
|